Influence of Oxidative Stress and Nutrition Biomarkers on the Cognitive Decline Evolution in Alzheimer Disease
NCT02800395 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 350
Last updated 2021-04-30
Summary
According to several reports, the oxidative stress and the nutrition could have an impact in the Alzheimer disease.
The association of these two parameters measurements and the cognitive impairment decline could help in a predictive diagnosis of cognitive decline evolution in patients presenting cognitive disorders.
This is a monocentric prospective "routine care" clinical trial on patients showing cognitive troubles especially memory complaints.
The objective is to demonstrate a correlation between oxydative stress and nutrition biomarkers and the clinical evolution of patients complaining of cognitive impairments.
The neuropsychologic data collection (the mini mental Status Examination (MMSE), the clock test, the Grober-Buschke test (FCSR-IR), the executive function evaluated by the Trail making test, and the medical imaging (by magnetic resonance imaging (MRI) or tomography in case of MRI contraindication) will be realized during the study inclusion phase in the usual intake of patients. Whole blood samples for the oxydative and nutrition biomarkers measurements will be taken at the study inclusion day during the stay at the Day hospital dedicated to the routine intake of patients issued from the memory consultation.
In this study, the principal evaluation criteria will be the MMSE score evolution during the 60 months of the patients follow-up, measured during the routine visits scheduled approximately every 6 months, according to the french national authority for health recommendations. It will allow evaluating the correlation between the cognitive decline evolution measured by MMSE during the Alzheimer disease or related diseases method during the 2 years follow-up, and the oxydative stress blood markers.
Conditions
- Alzheimer Disease
Interventions
- PROCEDURE
-
Malnutrition screening and perioperative nutritional support
* Multidisciplinary training sessions for malnutrition and malnutrition risk screening, postoperative nutritional procedures according to the ESPEN Guidelines * Preoperative Geriatric evaluation : eligibility criteria, nutritional status, previous history, comorbidities, clinical examination, activities of daily living (ADL) and Instrumental activities of daily living (IADL) * Implementation of an adapted nutritional support based on ESPEN Guidelines
Sponsors & Collaborators
-
Hospices Civils de Lyon
lead OTHER
Principal Investigators
-
Marc BONNEFOY, Pr · Hospices Civils de Lyon
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-12-31
- Primary Completion
- 2026-12-31
- Completion
- 2026-12-31
Countries
- France
Study Locations
More Related Trials
-
Returning Research Results That Indicate Risk of Alzheimer Disease Dementia to Healthy Participants in Longitudinal Studies
NCT04699786 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
A Brief Study To Evaluate The Safety, Tolerability, And Blood Levels Of Multiple Doses Of PF-044467943 Or Placebo In Combination With Donepezil In Subjects With Mild To Moderate Alzheimer's Disease
NCT00988598 ·Status: COMPLETED ·Phase: PHASE1
-
BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.
NCT02337907 ·Status: COMPLETED ·Phase: PHASE2
-
Exploratory Clinical Study and Validation of Blood Biomarkers for Alzheimer's Disease
NCT07294586 ·Status: COMPLETED
-
Prediction of Cognitive Properties of Memantine for Neurodegenerative Diseases
NCT02288000 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of LY2886721 in Healthy Participants and Participants Diagnosed With Alzheimer's Disease
NCT01807026 ·Status: COMPLETED ·Phase: PHASE1
-
A Clinical Trial for an Evaluation of Choline Alfoscerate and Donepezil for Cognitive Improvements of Patients With Cerebrovascular Injury in Alzheimer Patients
NCT02648906 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study of Donepezil Hydrochloride in Patients With Dementia Associated With Cerebrovascular Disease
NCT02660983 ·Status: COMPLETED ·Phase: PHASE4
-
Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment
NCT00149175 ·Status: COMPLETED
-
Clinical Trial of a Low Protein Diet in Patients With Cognitive Impairment
NCT05480358 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
COMPARATIVE EFFECTIVENESS OF MCI and DEMENTIA TREATMENTS IN A COMMUNITY-BASED DEMENTIA PRACTICE
NCT02860338 ·Status: COMPLETED
-
Dementias and Microbiota Composition: Is Possible to Revert the Dementia Symptoms Reverting the Microbiota Composition?
NCT05943925 ·Status: UNKNOWN
-
Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease
NCT01082965 ·Status: TERMINATED ·Phase: NA
-
A Based on PEEG and PET Study of Anxiolytic Treatment to Improve Cognitive Function in Patients With Alzheimer Disease
NCT03151382 ·Status: UNKNOWN ·Phase: PHASE4
-
Effects of a Nutraceutic Compound on Cognitive Impairment
NCT06200883 ·Status: COMPLETED ·Phase: PHASE4
-
Biomarker-based Trial of NPC-1 for Alzheimer's Pathology
NCT07236190 ·Status: RECRUITING ·Phase: PHASE2
-
APOE in the Predisposition to, Protection From, and Prevention of Alzheimer's Disease
NCT04994847 ·Status: ENROLLING_BY_INVITATION
-
Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo
NCT02240693 ·Status: COMPLETED ·Phase: PHASE2
-
A Randomized, Placebo-Controlled Trial to Examine the Efficacy of Oral Donepezil in Subjects With MCI
NCT00483028 ·Status: COMPLETED ·Phase: NA
-
Effect on Cognitive Performance and Safety/Tolerability of SSR180711C in Mild Alzheimer's Disease
NCT00602680 ·Status: TERMINATED ·Phase: PHASE2
-
A Multicenter Study on the Diagnosis and Intervention of New Biomarkers on the Prodromal Stage of Alzheimer's Disease
NCT04137926 ·Status: UNKNOWN ·Phase: NA
-
Effectiveness of A Nutritional Brain Metabolic Enhancer for Alzheimer Disease
NCT00013923 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Effects of MK-0249 and an Alzheimer's Disease Medication on Cognitive Function in Adults With Alzheimer's Disease (MK-0249-023)
NCT00874939 ·Status: TERMINATED ·Phase: PHASE1
-
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
NCT01561430 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Pilot Study About Extra Virgin Olive Oil "Coratina" in Mild Cognitive Impairment and Alzheimer's Disease Patients
NCT04229186 ·Status: UNKNOWN ·Phase: NA